As we hit the Q2/Q3 mark in this very hot summer, the hires chatter is not exactly heating up, but we did see a steady beat of news in July, including a lot of new CEOs.
With FDA approval, Ipsen's marathon effort to bring palovarotene to market for the rare disease fibrodysplasia ossificans progressiva (FOP) has finally crossed the finish
Rumours that German pharma Stada may be up for sale have been all but confirmed by the company's chief executive, who told a news agency that "exploratory talks" are takin
Italy's billionaire Agnelli family has taken a 15% stake in Dutch electronics company Royal Philips, in what is being viewed as a much-needed vote of confidence in its dec
Pharma industry bodies have slammed a proposal by the European Commission to set up a compulsory licensing (CL) framework for medicines in emergency situations, claiming t
US medical device company HDL Therapeutics is aiming to list on the Nasdaq via a merger with Swiftmerge Acquisition, a special purpose acquisition company (SPAC).
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.